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Abstract
Microglia, brain cells of nonneural origin, orchestrate the inflammatory response to diverse
insults, including hypoxia/ischemia or maternal/fetal infection in the perinatal brain. Experimen-
tal studies have demonstrated the capacity of microglia to recognize pathogens or damaged cells
activating a cytotoxic response that can exacerbate brain damage. However, microglia display
an enormous plasticity in their responses to injury and may also promote resolution stages of
inflammation and tissue regeneration. Despite the critical role of microglia in brain pathologies,
the cellular mechanisms that govern the diverse phenotypes of microglia are just beginning to
be defined. Here we review emerging strategies to drive microglia toward beneficial functions,
selectively reporting the studies which provide insights into molecular mechanisms underlying
the phenotypic switch. A variety of approaches have been proposed which rely on microglia
treatment with pharmacological agents, cytokines, lipid messengers, or microRNAs, as well on
nutritional approaches or therapies with immunomodulatory cells. Analysis of the molecular
mechanisms relevant for microglia reprogramming toward pro-regenerative functions points to
a central role of energy metabolism in shaping microglial functions. Manipulation of metabolic
pathways may thus provide new therapeutic opportunities to prevent the deleterious effects of
inflammatory microglia and to control excessive inflammation in brain disorders.
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1 | INTRODUCTION
Microglia are self-renewing, long-lived cells (Bruttger et al., 2015),
which stem from a unique nonhaematopoietic yolk-sac-derived cell
lineage, as indicated by elegant fate-mapping studies (Ginhoux et al.,
2010; Kierdorf et al., 2013; Schulz et al., 2012). They are critical both
for developmental processes such as synaptogenesis and for the
maintenance of neural homeostasis (Ekdahl, Kokaia, & Lindvall, 2009;
Nikolakopoulou, Dutta, Chen, Miller, & Trapp, 2013; Ribeiro Xavier,
Kress, Goldman, Lacerda de Menezes, & Nedergaard, 2015; Sellner
et al., 2016; Sierra et al., 2010; Tremblay et al., 2011).
Contributions of microglia to physiological brain function are
underlined by functional deficits in neuronal connectivity and neuro-
logic disorders in mice harboring dysfunctional microglia (Prinz & Pril-
ler, 2014), mutant for complement or CX3CR1 chemokine receptors
(Paolicelli et al., 2011; Schafer et al., 2012).
In response to insult or injury, microglia are capable of acquiring
diverse and complex phenotypes, allowing them to participate in cyto-
toxic response as well as in immune regulation or injury resolution
(extensively reviewed in (Q. Li & Barres, 2018; Wolf, Boddeke, & Ket-
tenmann, 2017; Colonna & Butovsky, 2017). The deleterious effects
of cytotoxic microglia include white and gray matter lesions in brain
tissue of both patients with chronic neuroinflammatory diseases such
as multiple sclerosis (MS) (Prins et al., 2015) and infants with perinatal
inflammation (Dean et al., 2010; Favrais et al., 2011). Conversely,
blockage of neuron damage after acute brain injury (Faustino et al.,
2011; Imai et al., 2007; Szalay et al., 2016) and promotion of remyeli-
nation in mice with myelin lesions (Butovsky et al., 2006; Miron et al.,
2013; Olah et al., 2012), reviewed in (Cherry, Olschowka, & O'Banion,
2014), are among supportive functions of pro-regenerative microglia.
Consolidated evidence indicates that the pro-inflammatory cyto-
kine interleukin (IL)-1β, the toll-like-receptor (TLR)-4 agonist
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lipopolysaccharide (LPS), the TLR-3 agonist Poly I : C, and tumor
necrosis factor-α (TNFα) are potent inducers of detrimental microglial
phenotype in vitro. Functionally, pro-inflammatory microglia are char-
acterized by microbicidal, antigen-presenting and immune-
potentiating abilities, through synthesis of nitric oxide (NO), chemo-
kines, and inflammatory cytokines (Amici, Dong, & Guerau-de-Are-
llano, 2017). Conversely, the anti-inflammatory cytokines IL-4 and IL-
13, immune complexes, IL- 1R ligands, IL-10, TGF-β, and glucocorti-
coids are typical agents which drive microglia toward pro-regenera-
tive, immunomodulatory or deactivated phenotypes. Pro-regenerative
microglia secrete anti-inflammatory mediators and express Arg1
instead of inducible NO synthase (iNOS), switching arginine metabo-
lism from production of NO to ornithine and polyamines for collagen
and extracellular matrix synthesis. However, detrimental and pro-
regenerative microglia polarization in vitro is highly artificial and does
not reflect the real in vivo situation where microglia activation follows
a wide spectrum of phenotypes, which may be driven by diverse stim-
uli, as described for macrophages (Xue et al., 2014).
Using transcriptomic and proteomic approaches (Butovsky et al.,
2014; Gautier et al., 2012; Hickman et al., 2013; Krasemann et al., 2017)
the molecular signature of microglia in vivo has begun to be defined
under physiological and pathological conditions, including amyotrophic
lateral sclerosis (ALS) (Chiu et al., 2013), multiple sclerosis (MS), Alzhei-
mer's disease (AD) (Krasemann et al., 2017) or perinatal brain injury
(Krishnan et al., 2017). However, our understanding of the molecular
mechanisms that govern transition of microglia from detrimental to pro-
regenerative phenotypes both in vitro and in vivo remains limited. Much
more is known about cellular pathways controlling polarization in macro-
phages, the peripheral microglia counterparts, where it is increasingly
clear that metabolic activities co-define their effector state. Specifically,
in peripheral macrophages, mitochondrial oxidation is a determinant of
pro-regenerative polarization. Blocking oxidative metabolism abrogates
anti-inflammatory macrophage function without affecting the pro-
inflammatory state (Ghesquiere, Wong, Kuchnio, & Carmeliet, 2014). For
a detailed description of both classical and emerging pathways, including
metabolic pathways, relevant for macrophage phenotypes we refer the
readers to recent excellent reviews (Amici et al., 2017; Diskin & Palsson-
McDermott, 2018).
Despite the genetic profile of microglia differs profoundly from
that of macrophages (Yamasaki et al., 2014), recent evidence indicates
that energy production in mitochondria may be a determinant of pro-
regenerative/resolving differentiation also in microglia. In fact,
reduced mitochondrial oxygen consumption, reduced electron trans-
port, and mitochondrial ATP synthesis caused by deficiency in Clock
(Clk)1, a mitochondrial hydroxylase that is necessary for the biosyn-
thesis of ubiquinone (Hekimi, 2013; Lapointe & Hekimi, 2008), has
been linked to the acquisition of pro-inflammatory phenotype by
microglia. Importantly, the inflammatory state of Clk1 deficient micro-
glia relies on aerobic glycolysis, as it is abolished when glycolytic
metabolism is inhibited by knocking down hexokinase 2 (HK2), a key
rate-limiting enzyme for phosphorylating the glucose (J. J. Gu et al.,
2018). However, whether metabolic pathways may take central stage
in inducing a repair-supportive phenotype is not yet established.
In this review, we summarize emerging strategies able to redirect
microglia from detrimental to beneficial functions. As we learn more
about molecular mechanisms controlling microglia effector functions,
a central role of cell metabolism emerges, opening novel approaches
to target microglia therapeutically.
2 | RECEPTOR AND CHANNELS
PROMOTING ANTI-INFLAMMATORY
MICROGLIA FUNCTION
Multiple brain's signaling substances converge on microglia to actively
maintain or alter their functional state through a variety of neuro-
transmitter receptors and channels (Domercq, Vazquez-Villoldo, &
Matute, 2013). Here we focus on receptors and channels which are
involved in microglia reprogramming toward anti-inflammatory pheno-
type with a known mechanism of action.
2.1 | Histamine and other neurotransmitter
receptors
Histamine has a well-established role as neuron-to-glia alarm signal in
the brain and microglia constitutively express all four histamine recep-
tors (H1R, H2R, H3R, and H4R) (W. Hu & Chen, 2017). Apolloni
et al. recently demonstrated that histamine counteracts pro-
inflammatory microglia phenotype in the SOD1-G93A mouse model of
ALS. They showed that histamine not only reduces expression of both
NADPH oxidase 2 (NOX2), a super-oxide generating enzyme which
forms reactive oxygen species (ROS), and of NF-κB, the classical tran-
scription factor activated in pro-inflammatory microglia, but also
increases the anti-inflammatory genes (IL-10, ARG1, P2Y12, CD163,
and CD206) acting through H1R and H4R. Importantly, histamine exerts
beneficial action only in inflammatory SOD1-G93A microglia, which are
characterized by decreased H1R levels, while elicits a pro-inflammatory
effect in nontransgenic cells. In support to these findings a recent work
showed that histamine deficiency reduces the ramified/surveilling mor-
phology of microglia and the production of anti-inflammatory factors in
the striatum of knockout mice (Frick, Rapanelli, Abbasi, Ohtsu, & Pitten-
ger, 2016). With respect to the signal transduction mechanisms involved
downstream of H1R and H4R activation in ALS microglia, Apolloni, and
colleagues demonstrated a persistent ERK1/2 phosphorylation, which
accounts for downregulation of p-NF-κB (Figure 1).
Among other neurotransmitter receptors controlling microglia
polarization, recently reviewed by Liu et al. (Liu, Leak, & Hu, 2016),
GABA receptors are upregulated in response to brain injuries and act
via NOX4 activation (Mead et al., 2012). The endocannabinoid type
2 receptor (CB2) inhibits IL-6 and TNFα release from microglia
(Bisogno & Di Marzo, 2010; Mecha et al., 2018) and increases the
suppressive potency of myeloid-derived suppressor cells. Nicotinic
receptors, in particular α7 receptor (Y. Sun et al., 2013; King, Gille-
vet, & Kabbani, 2017), decreases p-NF-κB and its p65 subunit and
inhibits p38 mitogen-activated protein kinase (p38-MAPK), a key
player of inflammatory microglia response (Lawson, Dobrikova, Shvey-
gert, & Gromeier, 2013) (Figure 1), while upregulates antioxidant
genes, promoting a pro-regenerative microglial state (Z. Han et al.,
2014). Sphingosine-1-phosphate (S1P) receptors downregulate pro-
inflammatory cytokines and enhance pro-regenerative responses after
2532 FUMAGALLI ET AL.
intracerebral hemorrhage (Marfia et al., 2016; Noda, Takeuchi,
Mizuno, & Suzumura, 2013). The S1P receptor ligand FTY720 has been
recently shown to attenuate microglia-mediated neuroinflammation
after white matter ischemic injury and to promote oligodendrogenesis
via the transcription factor signal transducer activator of transcription
(STAT)3 (Qin et al., 2017) (Figure 1), one of the STAT transcription fac-
tors that regulate cytokine (El Kasmi et al., 2006) and chemokine (Kwon
et al., 2017) production. Of note, S1P is a known activator of mitochon-
drial function (Nema & Kumar, 2015), suggesting a possible contribu-
tion of enhanced respiratory function to microglia phenotypic switch.
2.2 | Neuropeptide/growth factor receptors
Neuropeptides and neurotrophins acting through specific receptors
are able to modulate microglial response by inhibiting the release of
inflammatory mediators while favoring development of an alternative
activation program (Carniglia et al., 2017; Rizzi et al., 2018). Specifi-
cally, the melanocortins α-MSH and NDP-MSH, both exerting their
actions through G protein-coupled receptors (GPCRs), were found to
induce expression of the metabolic enzyme Arg1 in microglia in the
retina (Kawanaka & Taylor, 2011) and in rat primary culture (Carniglia,
Durand, Caruso, & Lasaga, 2013). Arg1 induction was accompanied by
enhanced expression of the nuclear receptor peroxisome proliferator-
activated receptor gamma (PPAR-γ) (Szanto et al., 2010), and by
enhanced IL-10 release (Figure 1), known markers of pro-regenerative
microglia (see below).
The classical neurotrophin NGF, through activation of Trk-A
receptors was recently shown to steer microglia toward a neuropro-
tective and anti-inflammatory phenotype (Rizzi et al., 2018) (Figure 1),
being particularly effective in reverting the pro-inflammatory state of
FIGURE 1 Schematic representation of receptors and signaling pathways mainly contributing to anti-inflammatory polarization of microglia.
Stimulation of histamine receptors H1R and H4R induces persistent ERK1/2 phosphorylation, that leads to pNF-κB downregulation and reduces the
expression of NADPH oxidase 2 (NOX2), dampening pro-inflammatory responses. Similarly, the endocannabinoid type 2 receptor (CB2) induces
sustained ERK1/2 phosphorylation causing pNF-κB downregulation. GABA receptors are also involved in reducing microglia reactivity through the
activation of NOX4. The nicotinic α7 receptor decreases pNF-κB and its p65 subunit and inhibits p38-MAPK. Blocking the voltage independent
KCa3.1 channels and the voltage-gated Kv1.3 also results in inhibition of p38-MAPK pathway and of iNOS and COX expression. IL-10, upon binding
of its receptor, suppresses pro-inflammatory cytokine production through induction of suppressor of cytokine signalling (SOCS)1 and (SOCS)3
proteins. These proteins, in turn, inhibit the cytokine-activated Janus kinase (JAK)/ STAT-1 signaling pro-inflammatory pathway. The transcription
factor signal transducer and activator of transcription (STAT) 3 is instead induced by the activation of sphingosine-1-phosphate (S1P) receptors
through its ligand FTY720, resulting in attenuation of microglia-mediated neuroinflammation. NGF, through activation of Trk-A receptor, reduces
cytokine/chemokine secretion, microglia motility, phagocytosis, and degradative pathways. The activation of the tyrosine kinase AXL receptor by
pro-resolving lipid mediators suppresses the pro-inflammatory microglial phenotype by dampening type I interferon (IFN) signaling. The
melanocortins α-MSH and NDP-MSH, through G protein-coupled receptors, enhance PPAR-γ, and Arg1 expression and promote IL-10 release.
Upon stimulation with IL-4, IL-4 receptor (IL-4R) induces activation of STAT-6, with consequent increase in Arg1, mannose receptor CD206 and
PPAR-γ expression and with induction (and release) of anti-inflammatory cytokines like IL-4, IL-10, IL-13. For specific references see text [Color
figure can be viewed at wileyonlinelibrary.com]
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microglia induced by β-amyloid. Importantly, the receptor signaling
activated by NGF in primary culture and ex vivo not only regulates a
number of microglia activities, such as cytokine/chemokine secretion,
motility, phagocytosis, and degradative pathways but also controls
microglia–neuron interaction, protecting neurons against Aβ-induced
spine alterations and synaptic dysfunction.
2.3 | Receptors of endogenous immune signals
IL-4 and IL-13 are endogenous immune signals which polarize micro-
glia toward neuron protective, pro-regenerative phenotype. Despite
microglia responsiveness to these cytokines have been studied mostly
in culture, microglia have been shown to respond to IL-4 administra-
tion with the expression of genes typical of alternative activation also
in vivo (Pepe, Calderazzi, De Maglie, Villa, & Vegeto, 2014). The phe-
notypic features of IL-4-treated microglia are controlled by a network
of molecular pathways that impact gene expression and cellular
metabolism (Figure 1). Among them, the transcription factor STAT
6 accumulates in response to IL-4 and, along with its downstream
effector PPAR-γ, has a central role in the regulation of transcription of
anti-inflammatory and pro-resolving genes (Figure 1) (Lan, Han, Li,
Yang, & Wang, 2017). The specific role of PPAR-γ in driving positive
metabolic and immune microglial functions will be discussed in a sub-
sequent section. Additionally, IL-4 induces expression of CD36, a
receptor of lipoproteins, whose uptake and metabolism may support
fatty-acid oxidation, contributing to metabolic microglia reprogram-
ming (Figure 2); (S. C. Huang et al., 2014).
IL-10 drives microglia toward an alternative activated phenotype,
which mainly participates in phagocytosis and removal of tissue debris
(Chhor et al., 2013). IL-10 suppresses pro-inflammatory cytokine pro-
duction from microglia via induction of suppressor of cytokine signal-
ing (SOCS)1 and (SOCS)3 proteins. SOCS1,3 act in a negative
feedback loop, inhibiting the cytokine-activated Janus kinase (JAK)/
STAT-1 signaling pathway that are activated upon binding of pro-
inflammatory cytokines to their specific receptors (Figure 1).
Both IL-4/IL-13 and IL-10 represent the challenging opportunities
to convert microglia toward protective functions.
2.4 | Triggering receptor expressed on myeloid
cells-2
Initial studies showed that protective microglial phenotype is induced
by signals derived from apoptotic cells that activate the triggering
receptor expressed on myeloid cells-2 (TREM-2). However, subse-
quent evidence (Krasemann et al., 2017) revealed that TREM-2 activa-
tion by apolipoprotein E (APOE), the major risk factor for AD,
identified as a TREM2 ligand (Atagi et al., 2015; Bailey, DeVaux, &
Farzan, 2015), drives a neurodegenerative phenotype in microglia,
characterized by suppression of major transcription factors of homeo-
static microglia (PU.1, MEF2a, SMAD3, and TGF-β signaling) and over-
lapping to some extent the classical pro-inflammatory microglia
phenotype, featured by high expression of the pro-inflammatory
miRNA miR-155 (Butovsky et al., 2012). Thus, targeting of the
TREM2-APOE pathway might serve as a way to restore homeostatic
microglia.
On the contrary, other studies revealed that TREM-2 deficiency, by
limiting microglia activation and phagocytosis, facilitates Aβ plaque
buildup, and injury of adjacent neurons in mouse model of AD (Jay, von
Saucken, & Landreth, 2017; Ulrich et al., 2014; Y. Wang et al., 2015;
Y. Wang et al., 2016; Yuan et al., 2016) and results in impaired elimi-
nation of supernumerary synapses during brain development (Filipello
et al., 2018). Interestingly the results coming from studies on
TREM2-deficient microglia showed reduced mitochondrial mass and
increased phosphorylation of adenosine monophosphate-activated
protein kinase (AMPK) (Ulland et al., 2017), a key regulator of energy
metabolism that is activated in response of low glucose and inhibits a
shift in the cellular metabolism from oxidative phosphorylation to gly-
colysis (Hardie, 2011a, 2011b).
Importantly, these metabolic changes were reverted by support-
ing ATP synthesis, suggesting that microglia dysfunctions caused by
TREM-2 deficiency depend on energetic compromise (Ghosh, Castillo,
Frias, & Swanson, 2017).
2.5 | Potassium channels
The expression of Ca2+-dependent K+ channel (KCa3.1) and K+ chan-
nels Kv 1.3 varies during microglia activation and can be a determinant
for microglia polarization (Nguyen et al., 2017). KCa3.1 channels are
voltage independent and only require a small increase in intracellular
calcium to open. By maintaining a negative membrane potential
through K+ efflux, the channels provide the driving force for prolong
calcium influx which typically occurs during microglia respiratory burst
(oxygen consumption by mitochondria) (Khanna, Roy, Zhu, & Schlich-
ter, 2001), migration (Schilling, Stock, Schwab, & Eder, 2004), prolifer-
ation (Maezawa & Jin, 2010), and NO production (Maezawa & Jin,
2010), features of classical pro-inflammatory microglia. Also the
voltage-gated potassium channel Kv1.3 through K
+ efflux helps to
maintain a negative membrane potential (Maezawa et al., 2018), thus
contributing to a pro-inflammatory microglia phenotype. Both KCa3.1
and Kv1.3 channels attracted interest as pharmacological targets for
inhibiting detrimental microglia action in different pathological condi-
tions, including spinal cord injury (Bouhy et al., 2011), ischemia
(Y. J. Chen, Raman, Bodendiek, O'Donnell, & Wulff, 2011; Y. J. Chen
et al., 2015), AD as well as cerebrovascular and traumatic brain injuries
(Dale, Staal, Eder, & Moller, 2016; Maezawa et al., 2018; Maezawa,
Jenkins, Jin, & Wulff, 2012; Nguyen et al., 2017). For example, KCa3.1
blockade with the small molecule TRAM-34 has been shown to have
beneficial effects in a rat MCAO ischemia model and to protect neu-
rons from neurotoxicity caused by microglia activated with β-amyloid
(Aβ) oligomers (Figure 1) (Maezawa, Zimin, Wulff, & Jin, 2011). Simi-
larly, the Kv1.3 specific blocker PAP-1 was recently shown to reduce
neuroinflammation, Aβ plaque load and to improve behavioural defi-
cits in a transgenic-mouse model of AD, a disorder characterized by
Kv1.3 upregulation in microglia (Figure 1) (Maezawa et al., 2011; Ran-
garaju, Gearing, Jin, & Levey, 2015). Inhibition of p38-mitogen-acti-
vated protein kinase (MAPK), iNOS and cyclooxygenase 2 (COX-2)
expression likely accounts for beneficial effects of the both KCa3.1
and Kv1.3 blockers (Figure 1) (Kaushal, Koeberle, Wang, & Schlichter,
2007; Nguyen et al., 2017).
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2.6 | Nuclear PPARs-γ
As mentioned above, PPARs-γ are nuclear receptors highly expressed
in microglia, that play important roles in both the immune response
and cell metabolism (Agarwal, Yadav, & Chaturvedi, 2017; Drew, Xu,
Storer, Chavis, & Racke, 2006). Consolidated evidence indicates
that PPAR-γ activation by both natural and synthetic agonists,
including the small molecule SNU-BP, inhibits expression of surface
antigen and synthesis of inflammatory mediators (Bernardo & Min-
ghetti, 2006; Saijo, Crotti, & Glass, 2013; Q. Han et al., 2017;
Y. Luo, He, Kuang, Jiang, & Yang, 2014), while increases the
expression of the anti-inflammatory genes Arg-1 and IL-4
(G. J. Song et al., 2016) and promotes microglial phagocytic ability
(Figure 2).
PPARs-γ have been implicated in the phenotypic switch induced
in microglia by some neuroprotective natural compounds, such as
malibatol A, a resveratrol agonist (Pan et al., 2015) and galangin, a
molecule abundant in honey and medicinal herbs (Choi et al., 2017).
PPAR-γ-dependent microglia reprogramming toward beneficial
function accounts for better outcome in several preclinical models of
brain pathologies. The treatment of AD mice with the PPAR-γ agonist
pioglitazone, a drug used to treat type 2 diabetes, results in enhanced
capability of microglia to phagocyte Aβ (Yamanaka et al., 2012) and
cognitive improvement. Moreover, pioglitazone ameliorates the dis-
ease course in both the experimental autoimmune encephalomyelitis
(EAE) model of MS (Feinstein et al., 2002; Storer, Xu, Chavis, & Drew,
2005) and in mice subjected to chronic mild stress (Q. Zhao
et al., 2016).
PPARs-γ regulate inflammatory pathway in microglia by several
mechanisms. They block p-38MAPK inflammatory pathways, resulting
in decreased microglia reaction (Figure 2) (Ji et al., 2010) and reduce
the activation of the classical pro-inflammatory transcription factors
STAT-1 and NF-κB, which are known to mediate both LPS and IFNγ
inflammatory signaling in microglia (Bernardo & Minghetti, 2006).
However, the pivotal role of PPARs-γ in regulating the activation
state of microglia may be due to metabolic reprogramming, as
recently highlighted in macrophages, where PPAR-γ has been impli-
cated in mTOR-dependent fatty acid uptake and lipid metabolic
reprogramming, downstream activation of semaphorin 6D (Sema6D)
(Kang et al., 2018), a key regulator of alternative macrophage
polarization (Figure 2). Indeed, through interaction with down-
stream transcription factors and coactivators, PPARs-γ regulate the
expression of genes involved in glucose metabolism in mitochon-
dria and fatty acid oxidation (Monsalve, Pyarasani, Delgado-Lopez, &
Moore-Carrasco, 2013; Willson, Lambert, & Kliewer, 2001). Specifi-
cally, when activated by the full agonist pioglitazone, PPARs-γ
increase mitochondrial biogenesis, mitochondrial DNA content and
oxygen consumption through interaction with the PPAR-γ coactiva-
tor 1-alpha (PGC1α), the nuclear factor erythroid 2–related factor
1–2 (Nrf1–2), and mitochondrial transcription factors (mtTF)A
(Gleyzer, Vercauteren, & Scarpulla, 2005), regulating antioxidant
gene expression (Liddell, 2017) (Figure 2). In addition, PPAR-γ acti-
vation increases mithocondrial fission, which mediates removal
of damaged mitochondria and plays an important role in the
assembly of mitochondrial electron transport chain (Corona &
Duchen, 2016).
FIGURE 2 Intracellular receptors involved in beneficial microglia polarization. PPAR-γ stimulation, by both natural and synthetic agonists
(e.g., SNU-BP, pioglitazone, rosiglitazone, malibatol A, galangin), inhibits expression of inflammatory mediators, while increase the expression of
the anti-inflammatory genes Arg-1, IL-4 and the fatty acid transporter CD36. Inhibition of p38-MAPK, STAT-1 and NF-κB pathways are
additional mechanisms underlying the anti-inflammatory action of PPAR-γ in microglia. As in other cell types PPARs-γ may also interact with the
PPAR-γ coactivator 1-alpha (PGC1α), the nuclear factor erythroid 2–related factor 1–2 (Nrf1–2), and mitochondrial transcription factors (mtTF)A,
increasing mitochondrial functions. In addition in macrophages it mediates changes in lipid metabolism induced by mTOR kinase via Sema 6D
[Color figure can be viewed at wileyonlinelibrary.com]
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Upstream PPAR-γ expression, it has been identified msh-like
homeobox-3 (MSX3), a homeobox gene particularly upregulated in
pro-regenerative microglia, that acts as pivotal inducer for pro-
regenerative microglial state (Z. Yu et al., 2015).
3 | MOLECULAR MECHANISMS LINKING
RECEPTOR/CHANNEL ACTIVATION TO THE
BIOENERGETIC STATE OF MICROGLIA
Pharmacological analysis of microglia receptor/channel signaling cas-
cades points to p-NF-κB, p38 -MAPK, iNOS, COX-2, and NOX2 as
key inflammatory intracellular pathways downregulated by agents
which dampen microglia activation under pathological stimuli. Intrigu-
ingly, emerging evidence indicates that at least p-NF-κB, iNOS and
NOX2 activity are influenced by the bioenergetics state of microglia,
as clearly described in a recent review (Ghosh et al., 2017) (Figure 3).
In fact, NADPH generated via glucose metabolism through the
penthose phosphate pathway (PPP) is requisite cofactor for the pro-
duction of NO, by iNOS, and of superoxide, by NOX. Moreover, glu-
cose flux through glycolysis increases iNOS and pro-inflammatory
gene expression via NADH production (Shen et al., 2017). Specifically,
NADH promotes dimerization of C-terminal binding protein (CtBP), a
transcriptional corepressor which normally binds and inhibits p300
acetylase with resultant release of p300 from CtBP. Unbound p300
acetylates the p65 subunit of NF-κB and promotes its inflammatory
transcriptional activity (Figure 3). By these molecular mechanisms glu-
cose metabolism via glycolysis and PPP can be a determinant of the
pro-inflammatory microglia state. In support to this hypothesis, inhibi-
tion of glycolytic metabolism has been recently shown to abolish the
inflammatory state of microglia lacking Clk1 (R. Gu et al., 2017), as
already mentioned in the introduction paragraph.
The link between glucose metabolism in the cytoplasm outside
mitochondria and inflammation implicates that agents reprogramming
microglia toward protective functions would decrease glucose flux
through both glycolysis and the PPP in order to downregulate iNOS
and NOX2. This may cause a compensatory increase in glucose-based
energy production in mitochondria and fatty acid-based energy pro-
duction. Consistent with this hypothesis, PPAR-γ signaling pathway,
that is induced by agents which redirect microglia toward protective
functions, promotes biogenesis of mitochondria and mitochondrial
glucose metabolism, as mentioned above, and promote fatty acids
beta oxidation, linking pro-regenerative microglia phenotype to fatty
acid- and glucose-based energy production in mitochondria (Figure 2).
4 | ALIMENTARY COMPONENTS DRIVING
PRO-REGENERATIVE MICROGLIA FUNCTION
THROUGH METABOLIC REMODELING
Bioactive fatty acids derived from nutrition such as saturated (SFA) or
polyunsaturated fatty acids (PUFA) can cross the blood–brain barrier,
and directly influence microglia, as recently reviewed by (Nadjar, Leyr-
olle, Joffre, & Laye, 2017).
While SFA mainly act as pro-inflammatory stimuli (Z. Wang et al.,
2012; Gao et al., 2014), N-3 PUFAs and their metabolites have emerged
as anti-inflammatory modulators of microglial functions (Laye, Nadjar,
Joffre, & Bazinet, 2018). Independent of the inflammatory challenge
applied (e.g., hypoxia, interferon-y, amyloid-β), cultured microglia consis-
tently show decreased production of pro-inflammatory factors
(De Smedt-Peyrusse et al., 2008), decreased COX2 and iNOS activity
(Pettit, Varsanyi, Tadros, & Vassiliou, 2013; Zendedel et al., 2015) while
exibit typical features of anti-inflammatory microglia, like CD206 surface
expression and autophagy when treated with n-3 PUFAs (Chhor et al.,
2013; Inoue et al., 2017). Many in vivo studies confirm that N-3 PUFA
supplementation reduces detrimental microglia function (summarized in
(Laye et al., 2018). Although microglia express a wide range of lipid-
sensitive receptors and lipid metabolism-related genes (Mauerer, Walc-
zak, & Langmann, 2009; Mecha et al., 2015), the molecular link between
bioactive fatty acids and their effects in microglia has not been
completely clarified yet. Emerging evidence suggests that PUFAs can
drive a protective phenotype through the activation of CB2, which is
among microglial receptors reprogramming microglia toward beneficial
function (Guida et al., 2017; Mecha et al., 2015; Nunez et al., 2004) but
other receptors may be involved including ALX/FPR2 receptors
(Bisicchia et al., 2018) (Figure 1).
Molecular pathways for the anti-inflammatory effects of N-3
PUFAs include activation and overexpression of the protein deacetylase
sirtuin1 (SIRT1), with subsequent suppression of NF-κB via subunit p65
deacetylation (Figure 3); (Inoue et al., 2017). Inhibition of p38MAPK
inflammatory pathway and PPAR-γ activation are also in part responsi-
ble of protective effects of PUFAs and their products (Antonietta
Ajmone-Cat et al., 2012; De Smedt-Peyrusse et al., 2008). Given the
connection of NF-κB and PPAR-γ to the bioenergetics state of microglia
(Ghosh et al., 2017), also dietary lipids may likely shape microglia pheno-
type acting on cell metabolism. In support to this hypothesis, fasting and
ketogenic diet, that lead to a sustained reduction in blood glucose levels
and to an increase in circulating ketones, have been reported to have
anti-inflammatory actions and suppress activation of microglia by regu-
lating their metabolic features (Longo & Mattson, 2014). These effects
have been shown to rely on the activation of the metabolite receptor
GPR109A by B-hydroxybutyrate, that attenuates NF-κB signaling and
pro-inflammatory cytokine production (Fu et al., 2015) (Figure 1).
Other groups of bioactive compounds, normally present in foods,
especially in the Mediterranean diet, such as phenolic compounds,
phytosterols and carotenoids (e.g., lycopene, fucoxanthin, and lutein)
exhibit anti-inflammatory properties on microglia (Pena-Altamira et al.,
2017; Jeong et al., 2010; Sachdeva & Chopra, 2015; D. Zhao, Kwon,
Chun, Gu, & Yang, 2017), but the mechanisms underlined their effects
still remain to be defined.
5 | MicroRNAs PROMOTING PRO-
REGENERATIVE MICROGLIA PHENOTYPE
AND THEIR POTENTIAL LINK WITH ENERGY
METABOLISM
MicroRNAs (miRNAs) are endogenous, short, noncoding RNAs that
act as important posttranscriptional regulators of gene expression,
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playing crucial roles in both the brain (Cao, Li, & Chan, 2016; Schratt,
2009) and the immune system (Xiao & Rajewsky, 2009). Due to their
ability to simultaneously modulate the fate of different genes, these
molecules are particularly well suited to act as key regulators during
neural and immune cell differentiation and activation.
The impact of miRNAs on microglial phenotype has been recently
revealed by generating mice lacking microglial Dicer, an enzyme nec-
essary for miRNA maturation. Dicer ablation resulted in hyper-
responsiveness of adult microglia to stimuli (peripheral endotoxin),
indicating that miRNAs overall limit microglia responses to challenge
(Varol et al., 2017). A number of studies dissected the role of specific
miRNAs in microglia (Guedes, Cardoso, & Pedroso de Lima, 2013;
Karthikeyan, Patnala, Jadhav, Eng-Ang, & Dheen, 2016; Ponomarev,
Veremeyko, & Weiner, 2013). Given the central role of cellular metab-
olism in the effector function of microglia, we focus below on
anti-inflammatory miRNAs induced in response to either pro- or anti-
inflammatory stimuli, which switch microglia toward protective func-
tions and that may act by modulating bioenergetic metabolism (listed
in Table 1).
MiR-124 was one of the first miRNA to be linked to pro-
regenerative microglial phenotype (Y. Sun, Luo, Guo, Su, & Liu, 2015).
It is absent in perinatal microglia but present at high levels in adult
microglia where it is strongly downregulated under inflammatory con-
ditions (~70% decrease in EAE mice) (Ponomarev, Veremeyko, Barte-
neva, Krichevsky, & Weiner, 2011). Its forced expression
downregulates pro-inflammatory markers, while increases the expres-
sion of protective markers, as is the case of TGF-β, Arg1, and FIZZ1
(Y. Sun et al., 2013; Ponomarev et al., 2011; S. Huang et al., 2018;
Periyasamy et al., 2018) and reduces microglial phagocytic ability
(Pinto, Cunha, Barbosa, Vaz, & Brites, 2017; Svahn, Giacomotto, Grae-
ber, Rinkwitz, & Becker, 2016). The contribution of miR-124 to
homeostatic/anti-inflammatory microglia functions relies on silencing
FIGURE 3 Metabolic drugs and molecular pathways exploitable to drive microglia into a pro-regenerative phenotype. Dichloroacetate (DCA)
promotes glucose metabolism in mitochondria by increasing the flux of pyruvate. Dimethylfumarate (DMF) promotes an antioxidant response and
mitochondrial biogenesis through activation of the Nrf2 pathway. It may also enhance TCA cycle by increasing the TCA cycle intermediate
fumarate. Metformin promotes oxidative phosphorylation through AMPK activation. Aldose reductase (AR) converts glucose into sorbitol using
NADPH as a cofactor. Sorbitol, in turn, activates the phospholipase C/protein kinase C signaling pathway, resulting in downstream activation of
pro-inflammatory NF-κB. By inhibiting AR, the small-molecule FMHM, Sorbinil, Zopolrestat, and Fidarestat, limit inflammatory microglia response.
Furthermore, Fidarestat induces CREB phosphorylation to increase Arg1. SIRT1 activators, such as Resveratrol, inhibit the pro-inflammatory NF-
kB pathway and activate fatty acid metabolism. The scheme also depicts how NF-kB, iNOS, and NOX activities are influenced by the
bioenergetics state of microglia. NADPH generated via glucose metabolism through PPP is a cofactor for the production of NO, by iNOS, and of
superoxide, by NOX. NADH generated through glycolysis promotes dimerization of C-terminal binding protein (CtBP), preventing the corepressor
activity of the monomeric form on the p300 acetylase, a NK-kB activator, with consequent activation of NF-kB transcriptional activity [Color
figure can be viewed at wileyonlinelibrary.com]
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TABLE 1 MicroRNAs with proregenerative functions in microglia and their metabolic targets
miRNA
Microglia
pro-regenerative
function Reference
Metabolic
target gene Metabolic pathway Model Reference
miR-124 Downregulates
IL-6, TNF-α,
iNOS
Sun et al., 2013;
Ponomarev
et al., 2011;
Huang et al.,
2018
RPIA Pentose phosphate
shunt
Human colorectal
cancer cells
Qiu Z. Et al., 2015
Increases TGF-β,
arginase-1, and
FIZZ1
Ponomarev et al.,
2011
PRPS1, PDK1 Lactate production Human colorectal
cancer cells
Qiu Z. Et al., 2015
Reduces motility
and phagocytosis
capacity
Svahn et al., 2015;
Pinto et al.,
2017
Targets C/EBPa Zhang P et al.,
2004; Yu A
2017
Supresses
p38-MAPK
Lawson SK et al.,
2013
miR-200b Reduces iNOS
expression and
NO production
Jadhav SP et al.,
2014
LDHA Aerobic glycolysis Glioma cells Hu S et al., 2016
Suppresses c-Jun
and JNK activity
Reduces the
migratory ability
miR-146a Targets the key
inflammatory
regulators
IRAK1/2 and
TRAF6
Jayadev et al.,
2013; Sharma N
et al., 2015
Undefined Glycolysis Synovial fibroblasts Saferding V 2017
Negatively
regulates IL-6
and TNF-α
Zhao H et al.,
2013
FAS Fatty acid synthesis Mesenchymal stem
cells; germinal
center B cells
Suzuki Y
et al.,2010; Guo
et al., 2013
miR-223 Increases Arg1 and
IL-10 expression
Wei Ying et al.,
2015
Undefined Glycolysis Macrophages Zhuang G et al.,
2012
Suppresses
PKNOX1, NFAT
and RASA1
It is required for
PPARγ function
Zhuang G, 2012
miR-181a Down-regulates
IL-1α
Xie et al., 2013 IDH1 NADPH production Mouse embryonic
fibroblasts
Chu B et al., 2015
Inhibits levels of
IL-1b, IL-6, and
TNFa
Oxidative
metabolism
Colon cancer cells;
hepatocytes
Wei Z et al., 2014;
Du X et al., 2017
Targets C/EBPα
and KLF6
Jia Bi et al., 2016
Increases PPARy
levels
miR-let-7 Inhibits INOS and
IL-6 expression
Cho KJ et al., 2015 PDK1, insulin-
PI3K-mTOR
pathway,
EZH2, IRS2
Glucose uptake and
lactate
production
Human
hepatocellular
carcinoma,
C2C12
myoblasts,
human
embryonic stem
cell-derived
cardiomyocytes
Ma X et al., 2014;
Zhu H et al.,
2011;
Kuppusamy KT
et al., 2015
Reduces ROS,
and enhances
IL-10, IL-4
Ppargc1b Gluconeogenesis,
beta-oxidation of
fatty acids and
ketogenesis
during fasting
Human
adipose-derived
mesenchymal
stem cells
Wei J et al. 2014
(Continues)
2538 FUMAGALLI ET AL.
of CCAAT/enhancer-binding protein (C/EBP)-α (P. Zhang et al., 2004),
one of the major transcription factor that drives pro-inflammatory micro-
glia polarization (A. Yu et al., 2017). Moreover, miR-124 suppresses
p38-MAPK, that also has central role in coordinating inflammatory
microglia responses (Lawson et al., 2013). Of relevance for metabolic
microglia reprogramming, miR-124 (Qiu et al., 2015) directly controls the
bioenergetic state of the cells. Specifically, it reduces lactate production
and the PPP, that supports NO and superoxide production, by targeting
mRNAs encoding phosphoribosyl pyrophosphate synthetase 1 (PRPS1)
and ribose-5-phosphate isomerase-A (RPIA) (Qiu et al., 2015); (Table 1).
MiR200b reduces iNOS expression and NO production and limits
the migratory potential of reactive microglia. Suppression of the gly-
colytic enzyme lactate dehydrogenase A (LDHA) and aerobic glycoly-
sis likely underlies the miRNA action (S. Hu et al., 2016); (Table 1).
MiR-146a is a microglia-enriched miRNA (Jovicic et al., 2013)
induced in inflammatory microglia, which dampens inflammation by
suppressing the key inflammatory proteins interleukin-1 receptor
associated kinase 1 (IRAK1) and TNF receptor associated factor-6
(TRAF-6) (Jayadev et al., 2013; Sharma, Verma, Kumawat, Basu, &
Singh, 2015). In addition, miR-146a may promote microglia transition
toward pro-regenerative traits by enhancing mitochondrial energy
metabolism and fatty acid oxidation. This intriguing hypothesis is sup-
ported by recent evidence showing (a) miR-146a-dependent PPAR-γ
upregulation at both protein and mRNA levels (C. Huang et al., 2016);
(b) positive correlation between circulating levels of miR-146a and
metabolic TCA cycle intermediates, which are indicative of intense
glucose metabolism in mitochondria (Wu et al., 2015); and (c) the
ability of the miR-146a to inhibit glycolytic activity (Saferding et al.,
2017) and to reduce fatty acid synthesis, via FASN silencing (Guo
et al., 2013; Suzuki, Kim, Ashraf, & Haider, 2010) (Table 1).
MiR-223 is another microglia-enriched miRNA (Jovicic et al.,
2013; Prada et al., 2018) that promotes anti-inflammatory gene
expression (Table 1). Its deficiency leads to compromised pro-
regenerative differentiation in response to IL-4 (Zhuang et al., 2012).
Three important inflammatory genes are validated miR-223 targets:
the pro-inflammatory regulator PBX/knotted 1 homeobox 1 (Pknox1)
(Zhuang et al., 2012), the transcription factor NFAT5, that is involved
in NF-κB signaling (Lopez-Rodriguez et al., 2001) and RAS p21 protein
activator 1 (RASA1), a crucial component of pro-inflammatory path-
ways in macrophage (Ying et al., 2015). Importantly miR-223 has been
shown to be required for PPAR-γ function (Zhuang et al., 2012), link-
ing the acquisition of pro-regenerative traits to mitochondrial glucose
metabolism and fatty acid beta oxidation.
miR-181a targets the inflammatory genes IL-1α (Xie et al., 2013),
TNF (He et al., 2013) and the transcriptional factor C/EBPα but also sup-
presses Kruppel-like factor 6 (KLF6) (Bi et al., 2016), a PPAR-γ inhibitor
(Date et al., 2014), thus likely favoring PPAR-γ-dependent energy metab-
olism in mitochondria and fatty acid peroxidation in microglia. This has
been proven in lymphocytes where miR-181a enhances the expression
of genes involved in beta oxidation while suppresses isocitrate dehydro-
genase 1 (IDH1), a cytoplasmic enzyme involved in production of
NADPH, the cofactor for NO and superoxide generation (Lian et al.,
2016; Chu, Wu,Miao, Mei, &Wu, 2015; Table 1).
TABLE 1 (Continued)
miRNA
Microglia
pro-regenerative
function Reference
Metabolic
target gene Metabolic pathway Model Reference
Targets PAK and
C/EBPα
Banerjee et al.,
2013; Zhang W
et al., 2015
Suppresses the
release of
inflammatory
mediators
Lv J et al., 2018
miR-21 Suppresses IRAK
and MyD88 and
PDCD4
Chen et al., 2013;
Sheddy et al.,
2010
PEPCK;
G6Pase,
FOXO1
Glycolysis Hepatocytes Luo et al., 2017
Negatively
regulates TLR-4
signaling
Fafian-Labora J
et al., 2017
Suppresses FasL
expression
Zhang L,
et al. 2012
miR-29b Suppresses immune
responses to
intracellular
pathogens by
targeting IFN-k
Ma et al., 2011 PPARδ,
SPARC
Glycose uptake Skeletal muscle
cells, adipocytes
Zhou Y et al., 2016;
song H 2018
IRS1, PI3K,
and AKT2
Glycolysis Human and mouse
skeletal muscle
cells
Massart J et al.,
2017
PPARD Fatty acid oxidation Human and mouse
skeletal muscle
cells
miR-125a Not defined ENO-1, HK2,
PFK1
Glycolysis Hepatocellular
carcinoma cells
Jin et al., 2017
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let 7b belongs to the let 7 family of miRNAs, that dampens pro-
duction and release of inflammatory molecules from microglia
(Table 1). p21-activated kinase 1 (PAK) and C/EBP have been dis-
closed as downstream inflammatory targets of let 7 miRNAs
(Banerjee, Xie et al., 2013). However, let 7 miRNAs also serve as
important mediators in energetic metabolism (Chu et al., 2015). They
reduce glucose uptake and lactate production and prompt the use of
fatty acid as energy source. However, further work is required to
define how let 7b impacts microglia metabolism.
MiR-21 is one of the most common anti-inflammatory miRNAs
(Sheedy, 2015). It is a negative regulator of TLR-4 signaling (Fafian-
Labora et al., 2017), able to downregulate the expression of two
essential mediators for NF-κB activation, the TLR-4 adaptor protein
MyD88 and its downstream target IL1 receptor-associated kinase
(IRAK) (Y. Chen et al., 2013). In addition, miR-21 targets programmed
cell death protein 4 (PDCD4) (Sheedy et al., 2010) and the apoptotic
protein FasL (L. Zhang, Dong, Li, Hong, & Wei, 2012) protecting
against microglia-mediated neuron cell death in hypoxic/ischemic con-
ditions (L. Zhang et al., 2012). Despite the action on miR-21 on micro-
glia bioenergetic state is still undefined, miR-21 inhibits glucose
production by targeting phosphoenolpyruvate carboxykinase (PEPCK),
glucose-6-phosphatase (G6Pase), and forkhead box protein O1
(FOXO1) an important transcription factor of insulin signaling (A. Luo
et al., 2017); (Table 1).
miR-29b is upregulated in cultured microglia during neuroviral
infection (Thounaojam, Kaushik, Kundu, & Basu, 2014) and suppresses
immune responses to pathogens by targeting interferon-k (IFN-k)
(Ma et al., 2011). As other member of the miR-29 family, miR-29b
reduces glucose uptake (Zhou et al., 2016; H. Song, Ding, Zhang, &
Wang, 2018) and glycolysis (Massart et al., 2017). However, whether
miR-29 impacts glucose metabolism in a similar manner in microglia
remains still unknown.
Finally, miR-125-a, known to be involved in macrophage differen-
tial activation through downregulation of TNF-α-induced protein
3 (TNFAIP3) (Graff, Dickson, Clay, McCaffrey, & Wilson, 2012) and of
the inflammatory transcription factor Kruppel-like factor 13 (KLF13)
(Banerjee, Cui, et al., 2013), has been recently found to be upregulated
in reactive microglia and in extracellular vesicles (EVs) thereof (Prada
et al., 2018). Few glycolytic enzymes, including enolase-1 (ENO-1),
HK2 (F. Jin et al., 2017; C. M. Sun, Wu, Zhang, Shi, & Chen, 2017) and
phosphofructokinase (PFK1) are miR-125-a validated targets
(Table 1). Consistently, miR-125-a decreases the uptake of glucose
and the production of lactate, and the levels of ATP and ROS in other
cell types (F. Jin et al., 2017). Whether the miRNA suppresses glycoly-
sis in microglia remains to be proven.
6 | AN ATTRACTIVE CELL THERAPY
APPROACH TO REDIRECT MICROGLIA
TOWARD BENEFICIAL FUNCTIONS:
INVOLVEMENT OF ENERGY METABOLISM
Mesenchymal stem cells (MSCs) are widely used in cell therapy of
brain injury and inflammation thanks to their immunomodulatory
properties, their self-renewal, their multipotency and their minimally
invasive accessibility that make them an attractive tool for regenera-
tive medicine. A large part of MSC positive effects across models of
brain injury is due to their secretion products which create a favorable
regenerative microenvironment. MSC secretome includes soluble fac-
tors, released in a naked form, and molecules (proteins, lipids and
genetic material) released in association with EVs. EVs, including exo-
somes and microvesicles, are fundamental mediators of intercellular
communication. They shuttle bioactive molecules from one cell to
another, causing the exchange of information and reprogramming of
the recipient cells (Turola, Furlan, Bianco, Matteoli, & Verderio, 2012).
Previous findings from our group and others have shown that
through their secretome MSCs re-direct microglia from detrimental
toward pro-regenerative functions (Giunti et al., 2012; Zanier et al.,
2014). By investigating post-traumatic changes of microglia in mice
that had received MSCs through intracerebroventricular administra-
tion, we observed an increased number of Ym1(+) protective micro-
glia, associated with early and persistent recovery of neurological
functions. MSCs, indirectly co-cultured with microglia in vitro, directly
counteract the pro-inflammatory response of cells activated with
inflammatory cytokines and induce persistent pro-regenerative traits
(Giunti et al., 2012; Zanier et al., 2014). More recent studies demon-
strated that MSCs-derived EVs may be sufficient to significantly
dampen microglia response and improve functional recovery upon
intravenous administration in traumatic brain or spinal cord injuries
(L. X. Zhang, Yin, Zhang, & Deng, 2015; J. W. Kim, Ha, Molon, & Kim,
2013; Ruppert et al., 2018) as well as in a mouse model of
AD. Despite these findings offer a hopeful opportunity to advance
novel cell-free therapeutic strategies that might prevail over the risks
associated with the use of cells, a still unresolved issue is the molecu-
lar mechanism whereby the infused EVs reduce inflammation and res-
cue cognitive impairments in rodent models of neuroinflammatory
diseases. Indeed, EVs contain many active components and it is diffi-
cult to identify those with significant effects on microglia and other
brain cells (D. K. Kim et al., 2016).
An alternative source of stem cells able to redirect brain inflam-
matory myeloid cells (microglia and monocyte-derived cells) are neural
precursor cells (NPCs) (De Feo et al., 2017). Martino and coworkers
recently showed that intrathecal transplantation of NPCs in mice with
EAE restrains microglia activation and impairs the accumulation of
inflammatory monocyte-derived cells, favoring their switch toward an
anti-inflammatory phenotype. Transcriptome analysis, combined to
the use of TGF-β2 knockout neural progenitors, identified a secretory
protein, TGF-β2, as the primary factor responsible for NPC immuno-
modulation and disease amelioration. TGF-β2 is a well-known inducer
of Arg1, the key metabolic enzyme which distinguishes alternatively
activated myeloid cells (Gordon, 2003). Consistent with the presence
of TGF-β responsive elements in the flanking region of the metabolic
gene (Peranzoni et al., 2007), Martino and colleagues found by tran-
scriptome analysis an early upregulation of Arg1 in myeloid cells
exposed in vitro to NPCs, followed by subsequent induction of anti-
inflammatory molecules (e.g., Hspa1a, IL-1 decoy receptor that blocks
IL-1 [Il1r2] and the NF-κB inhibitor Ascc1). Moreover, a profound
rearrangement of metabolic and synthetic processes was observed
in vivo in myeloid cells FACS-sorted from EAE mice intrathecally
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injected with NPCs. In particular, oxidative phosphorylation was the
most prominent pathway altered under NPC treatment.
Very recently a significant progress has been made toward under-
standing the molecular mechanism that underpins the capacity of
NPCs to drive pro-inflammatory microglia and infiltrating macro-
phages toward beneficial functions in EAE (Peruzzotti-Jametti et al.,
2018). Pluchino and colleagues clearly showed that NPCs counteract
the metabolic changes of pro-inflammatory cells and reprogram them
toward an oxidative phosphorylation anti-inflammatory phenotype.
Indeed NPCs restore basal oxygen consumption rate and extracellular
acidification rate in pro-inflammatory macrophages. Furthermore, by
performing an untargeted mass spectrometry analysis of the extracel-
lular and intracellular metabolite content of macrophages, they identi-
fied the metabolite succinate as the main target of the pro-
regenerative NPC action. Intracellular succinate is known to act as a
key pro-inflammatory signal in phagocytes, by enhancing IL-1β gener-
ation (Littlewood-Evans et al., 2016; Tannahill et al., 2013) and favour-
ing mitochondrial production of ROS over ATP synthesis (E. L. Mills
et al., 2016). Extracellular succinate also exhibits pro-inflammatory
activity though interaction with its specific receptor SUCNR1 and it is
emerging as a biomarker of metabolic distress and inflammatory activ-
ity (Littlewood-Evans et al., 2016; E. Mills & O'Neill, 2014). Specifi-
cally, the work by Pluchino and colleagues demonstrated that
succinate is released by inflammatory phagocytes and activates
SUCNR1 on NPCs, leading to the acquisition of an anti-inflammatory
NPC phenotype. In fact, in NPCs SUCNR1 activation elicits both
secretion of the immune modulator PGE2, that in turn deactivates
pro-inflammatory phagocytes, and upregulation of two succinate co-
transporters (i.e., SLC13A3 and SLC13A5) which remove the extracel-
lular metabolite and prevent its autocrine and paracrine action on
inflammatory phagocytes. A significant decrease in succinate concen-
tration was reported in the CSF of EAE mice transplanted with NPCs
and the expression of SUCNR1 was shown to be necessary for the
therapeutic effects of transplanted NPCs in vivo. Besides identifying
scavenging of extracellular succinate as a novel anti-inflammatory
mechanism underlying the regenerative potential of NPCs, this work
provides a direct link between NPC-dependent phenotypic and meta-
bolic switch in microglia/macrophages.
7 | METABOLIC DRUGS AND MOLECULAR
PATHWAYS WHICH MAY BE EXPLOITED TO
DRIVE MICROGLIA INTO A NEURO-
SUPPORTIVE PHENOTYPE
Some metabolic pathways may be exploited to drive a pro-
regenerative microglia phenotype, and a few drugs may already be
available for metabolic microglia reprogramming (Table 2).
Dichloroacetate (DCA) is a small orally available drug with several
therapeutic applications including MS, solid tumors and inherited
mitochondrial disorders (James et al., 2017) based on its ability to
inhibit the kinase PDK1 and to consequently increase pyruvate dehy-
drogenase (PDH) activity and the flux of pyruvate into the mitochon-
dria (Gerriets et al., 2015; Kato, Li, Chuang, & Chuang, 2007);
(Figure 3). DCA has been shown to shifts glucose metabolism toward
the TCA cycle/oxidative phosphorylation in T cells in mice affected by
EAE (Gerriets et al., 2015) and to promote a pro-regenerative micro-
glia/macrophages phenotype in vitro and in a peripheral inflammation
model (Kato et al., 2007). However, whether DCA shifts microglial
phenotype by promoting oxidative phosphorylation has not been
proven yet.
Dimethylfumarate (DMF) is an approved drug for MS, known to
switch pro-inflammatory microglia to a neuroprotective state (Parodi
et al., 2015) and to reduce disease progression via activation of (ery-
throid-derived 2)-related factor-2 (Nrf2), a transcription factor with
antioxidant properties (Liddell, 2017). DMF has been proposed to
exert its therapeutic effects modulating oxidative phosphorylation,
through increased levels of the TCA cycle intermediate fumarate in
microglia (Tannahill, Iraci, Gaude, Frezza, & Pluchino, 2015); (Figure 3).
However, this intriguing hypothesis still remains to be validated.
Metformin is a widely used drug to treat diabetes and a well-
known activator of AMPK, already mentioned to be activated in
response of low glucose and to promote oxidative phosphorylation
(Hardie, 2011a, 2011b); (Figure 3) Metformin has been recently
shown to promote pro-regenerative microglial phenotype and signifi-
cantly ameliorate neurobehavioral function after stroke (Q. Jin et al.,
2014) and traumatic brain injury (Tao et al., 2018), suggesting that it
may be used to enhance pro-regenerative microglial function by pro-
moting oxidative metabolism.
PPAR-γ activation is an alternative way to push oxidative metabo-
lism in microglia, as already mentioned. PPARs-γ can be activated with
thiazolidinediones (e.g., pioglitazone or rosiglitazone) a class of antidia-
betic drugs proven to be effective in reducing the extent of neuroin-
flammation in different models of brain diseases and to attenuate
neurodegeneration in patients with mild-to-moderate dementia
(Heneka, Fink, & Doblhammer, 2015).
Protective microglial function may be also promoted by pharma-
cological inhibitors of aldose reductase (AR), a metabolic enzyme
implicated in inflammation-related diseases, that converts glucose into
sorbitol using NADPH as a cofactor (Petrash, 2004); (Figure 3). The
TABLE 2 Metabolic drugs for pro-regenerative microglia polarization
Targets Drugs References
PDK 1 (inhibitor) DCA Kato et al., 2007; Gerriets
et al., 2015
Nrf2 (activator) DMF Liddell, 2017
AMPK (activator) Metformin Hardie, 2011a, 2011b
PPARγ (agonist) Pioglitazone Heneka et al., 2015
Rosiglitazone Heneka et al., 2015
DSP-8658 Yamanaka et al., 2012
MDG548 Lecca et al., 2015
SNU-BP Bernardo & Minghetti,
2006
Aldose reductase
(inhibitor)
Small-molecule
FMHM
Zeng et al., 2013
Sorbinil X. M. Song et al., 2017
Zopolrestat X. M. Song et al., 2017
Fidarestat Q. Zhang et al., 2016
Tolrestat Rosa & Dias, 2014
Sirtuins (activator) Resveratrol Carafa et al., 2016
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small-molecule FMHM, a natural derived AR inhibitor, was initially
reported to suppress the expression of various inflammatory genes in
microglia both in vitro and in vivo. Mechanistically FMHM suppresses
the activity of AR-dependent phospholipase C/protein kinase C sig-
naling, resulting in downstream inactivation of NF-κB inflammatory
pathway (Zeng et al., 2013); (Figure 3). More recently, two other AR
inhibitors have been identified, Sorbinil and Zopolrestat, which signifi-
cantly inhibit inflammatory cytokine expression by blocking NF-κB
and MAPK signaling pathways in Aβ-treated microglia (X. M. Song
et al., 2017); (Figure 3). In support to these findings, Zhang and col-
leagues showed that AR deficiency drives microglia/macrophages
toward an anti-inflammatory after spinal cord injury in mice and treat-
ment with the AR inhibitor Fidarestat induces c-AMP response ele-
ment binding protein (CREB) phosphorylation to increase Arg1
expression in cultured microglia (Figure 3); (Q. Zhang et al., 2016).
Importantly some AR inhibitors have gone through Phase-3 clinical
studies (Pandey, Srivastava, & Ramana, 2012) and Tolrestat has been
approved to prevent diabetic complications (Rosa & Dias, 2014).
Finally, regulation of sirtuins (SIRTs) may represent another strategy
to promote protective microglial phenotype through metabolic remo-
deling. SIRTs are a family of NAD-dependent lysine deacetylases, that
play a key role in regulation of cellular metabolism among other fun-
damental cell function. SIRT1 and SIRT6 were reported to coordinate
a switch from glycolysis to fatty acid oxidation in macrophages
(J. Yu & Auwerx, 2009) and SIRT1 and 2 were shown to prevent
excessive microglia activation through NF-κB deacetylation (Figure 3);
(L. Li et al., 2015); (Inoue et al., 2017; Pais et al., 2013). Starting from
Resveratrol, the first SIRT1activator described, other SIRT activators
have been developed and some of them are currently in clinical trials
for the treatment of age-related neuroinflammation (Carafa
et al., 2016).
8 | CONCLUSIONS
A large variety of receptors are present in microglia, whose activation
by immune signals, neurotransmitters, neuropeptides, hormones, lipid
messengers, metabolites, and even alimentary components drives
microglia toward beneficial functions. Their signaling pathways con-
verge on common anti-inflammatory and pro-regenerative molecular
programs. While the nuclear receptor PPAR-γ, that promotes glucose
and fatty acid metabolism in mitochondria, is consistently induced, the
inflammatory pathways dependent on NF-κB, p38-MAPK, iNOS,
COX-2 and NOX2 are commonly inhibited. Importantly, iNOS, NOX2
and NF-κB activities are strictly connected to glucose metabolism
through glycolysis and the PPP, implicating that a change in microglia
bioenergetics would shape the microglia phenotype. Specifically
switching from aerobic glycolysis to oxidative phosphorylation would
dampen microglia pro-inflammatory activity.
A set of miRNAs with anti-inflammatory action has been identi-
fied. Among their validated target genes, we here highlighted many
metabolic enzymes involved in glucose uptake, glycolysis, lactate pro-
duction, pentose phosphate shunt, suggesting a connection between
miRNA-induced transition toward protective phenotype and changes
in energy metabolism.
Finally stem cells, (at least NPCs), which redirect microglia toward
protective function, induce a profound rearrangement of metabolic
and synthetic microglial processes, further supporting the key involve-
ment of bioenergetics in microglia reprogramming toward an alterna-
tive activation state.
From this scenario, targeting cell metabolism emerges as a new
potential therapeutic approach to redirect microglia from detrimental
to pro-regenerative phenotype. In this respect, two drugs shifting glu-
cose metabolism toward the TCA cycle/oxidative phosphorylation
(DCA and DMF) have already been approved for the treatment of MS,
the prototypical neuroinflammatory disease characterized by microglia
inflammation and drugs approved to treat metabolic disorders (met-
formin and thiazolidinediones) have been proven to dampen excessive
microglial activation in brain diseases.
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